Infection, Bacterial
80
11
13
39
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.0%
4 terminated out of 80 trials
90.7%
+4.2% vs benchmark
11%
9 trials in Phase 3/4
13%
5 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (80)
Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.
DACC in the REduction of Surgical Site INfection
A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis
ICIS in Burn Patients Compared to Other Inflammatory Markers
biomArkers to differeNtiate bacTerial From vIral iNfEctions
Development and Validation of (Bio)Sensors for the Identification of Pathogens
Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)
CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
ElastoMeric Infusion Pumps for Hospital AntibioTICs
Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy
Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)
Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue
Evaluating Newly Approved Drugs for Multidrug-resistant TB
Addition of Probenecid to Penicillin-V Therapy
Plasma Concentrations of Amoxicillin Administered in High-doses During the First Week of Treatment (MAX-AMOX)